证券日报网讯1月6日，康恩贝（600572）在互动平台回答投资者提问时表示，截至2025年12月31日，公 司股东总户数为79985户。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要提示内容： 1、本次行权股票数量：2025年第四季度，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"） 2022年股票期权激励计划（以下简称"本次激励计划"）激励对象行权且完成股份过户登记的股票数量合 计为963.8570万股。 2、本次行权股票上市流通时间：本次激励计划采用自主行权方式行权，激励对象（除公司董事、高级 管理人员外）行权所得股票于行权日（T日）后的第二个交易日（T+2）日可上市交易。 2025年第四季度，公司本次激励计划激励对象行权且完成股份过户登记的股票数量合计为963.8570万 股。有关情况公告如下： 一、本次激励计划已履行的决策程序及相关信息披露 （一）2022年9月15日，公司十届董事会第二十二次（临时）会议和十届监事会第十三次（临时）会议 分别审议通过了《关于〈浙江康恩贝制药股份有限公司2022年股票期权激励计划（草案）〉及摘要的议 案》及其他相关议案，公司独立董事、监事会、律师均发表了相关 ...

证券代码：600572 证券简称：康恩贝 公告编号：临2026-001 浙江康恩贝制药股份有限公司 关于2025年第四季度股票期权激励计划 自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要提示内容： 1、本次行权股票数量：2025年第四季度，浙江康恩贝制药股份有限公司（以下简称 "公司""本公司"）2022年股票期权激励计划（以下简称"本次激励计划"）激励对象 行权且完成股份过户登记的股票数量合计为963.8570万股。 2、本次行权股票上市流通时间：本次激励计划采用自主行权方式行权，激励对象（除 公司董事、高级管理人员外）行权所得股票于行权日（T日）后的第二个交易日（T+2）日 可上市交易。 2025年第四季度，公司本次激励计划激励对象行权且完成股份过户登记的 股票数量合计为963.8570万股。有关情况公告如下： 一、本次激励计划已履行的决策程序及相关信息披露 （一）2022年9月15日，公司十届董事会第二十二次（临时）会议和十届监 事会第十三次（临时）会议分别审议通过了《关于〈浙江康恩贝制 ...

Core Viewpoint - The Zhejiang Provincial Department of Science and Technology has announced the project list for the 2026 "Pioneer Leading Goose + X" technology plan, which includes a total of 441 projects, comprising 69 "Pioneer" projects, 309 "Leading Goose" projects, and 63 technology cooperation projects [1][2]. Group 1: Project Overview - The 2026 "Pioneer Leading Goose + X" technology plan includes 441 projects in total [1][2]. - The projects are categorized into three types: "Pioneer" projects, "Leading Goose" projects, and technology cooperation projects [1][2]. Group 2: Project Details - The "Pioneer" projects include advanced technologies such as high-consistency diamond NV sensor mass production technology and quantum sensor preparation research [5][6]. - The "Leading Goose" projects focus on environmental technology, including key technologies for the treatment of new pollutants in various industries [8][9]. Group 3: Implementation Guidelines - Project units are required to submit project task books through the Zhejiang Provincial Science and Technology Management Platform by specified deadlines, with penalties for late submissions [3][4]. - The management of funds must adhere to specific regulations to ensure proper allocation and usage [4].

Core Insights - The article discusses the competitive landscape of the hair medical industry in China, highlighting key players and market dynamics [1][5]. Group 1: Competitive Landscape - The Chinese hair medical industry features various competitive factions, with companies like Yonghe Medical, Damaik, and Qingyi focusing on hair transplant medical services, while SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Xianju Pharmaceutical are involved in medical nurturing services [1]. - In the hair transplant sector, the first tier consists of leading national chain brands such as Yonghe Medical, Bilian Sheng, and Damaik, which collectively hold a significant market share and possess nationwide direct chain layouts, mature technology systems, and strong brand recognition [1]. Group 2: Hair Growth Pharmaceuticals - In the hair growth pharmaceuticals market, the first tier includes SanSheng Pharmaceutical, Zhendong Pharmaceutical, and Merck, with the former two holding major shares in the minoxidil market, while Merck is recognized as the original manufacturer of finasteride [5]. - The second tier comprises Xianju Pharmaceutical, Kang En Bei, and Xiamen Meishang Pharmaceutical, which have accelerated the launch of minoxidil and finasteride products in recent years, gaining notable market recognition [5]. Group 3: Sales Performance - In the online pharmacy sector, Zhejiang SanSheng's minoxidil tincture product achieved sales exceeding 1 billion yuan, while Zhendong Anxin's minoxidil lotion surpassed 300 million yuan in sales, and SanSheng's minoxidil foam also exceeded 100 million yuan [9]. - In the offline market during the first quarter of 2025, Zhejiang SanSheng's minoxidil tincture and Zhendong Anxin's minoxidil lotion both recorded sales above 20 million yuan, with market shares of 50.61% and 38.82%, respectively [10]. - The sales ranking for minoxidil products shows Zhejiang SanSheng's minoxidil tincture leading with over 34 million yuan in sales (50.61% market share), followed by Zhendong Anxin's minoxidil lotion with over 26 million yuan (38.82% market share) [11].

证券代码：600572 证券简称：康恩贝 公告编号：临2025-078 浙江康恩贝制药股份有限公司 第十一届董事会第十四次（临时）会议 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司(以下简称"公司")第十一届董事会第十四次（临时）会议于2025年12月30 日以通讯方式召开。会议通知和延期召开会议通知分别于2025年12月17日和12月18日以书面、电子邮件 方式送达各董事。会议应参加审议表决董事9人，实际参加审议表决董事9人。会议的召开符合《公司 法》《公司章程》的规定。 会议经全体董事审议表决，通过决议如下： 一、审议通过《关于选举公司董事长、副董事长的议案》。表决情况：同意9票，反对0票，弃权0票。 选举应徐颉先生任公司第十一届董事会董事长、金军丽女士任公司第十一届董事会副董事长，任期自本 次董事会审议通过之日起至第十一届董事会任期届满之日止。 二、审议通过《关于选举代表公司执行公司事务董事的议案》。表决情况：同意9票，反对0票，弃权0 票。 选举应徐颉先生为代表公司执行公司事务的 ...

证券日报网讯 12月30日，康恩贝发布公告称，2025年12月30日，公司召开第十一届董事会第十四次 （临时）会议，全体董事一致同意选举应徐颉先生任公司第十一届董事会董事长、金军丽女士任公司第 十一届董事会副董事长；同意选举应徐颉先生为代表公司执行公司事务的董事，并担任公司法定代表 人，任期均自本次董事会审议通过之日起至第十一届董事会任期届满之日止。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 12月30日，康恩贝发布公告称，公司第十一届董事会第十四次（临时）会议审议通过 《关于选举公司董事长、副董事长的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 12月30日，康恩贝发布公告称，公司董事会于 2025 年 12 月 30 日收到公司副总裁徐春玲 女士递交的书面辞职报告，因到龄退休原因，徐春玲女士向公司董事会申请辞去副总裁职务。徐春玲女 士辞去副总裁职务后，将不再担任公司任何职务。 ...

Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]